World-Class Research Centre
for Personalized Medicine
2 Akkuratova street, St. Petersburg 197341
A unique targeted comprehensive panel of genes responsible for the development of hereditary pheochromocytomas and paragangliomas, as well as pituitary and parathyroid tumors will be created for sequencing using the next-generation sequencing (NGS) method.
A registry will be created for patients with chronic myeloid leukemia who failed TKI therapy, including those progressing to blast crisis; biobanking of blood and bone marrow samples will be performed.
Barcode libraries will be amplified and molecular cloning of genes of interest into plasmid vectors for expression in eukaryotic cells will be done for the subsequent implementation of the technology for sequencing single tumor cells.
A protocol will be prepared to study the immune profile in patients with acute leukemia, isolate individual groups of bone marrow immune cells (lymphocyte subsets, subsets of regulatory T-cells, separate subsets of cells of myeloid origin) using single-cell flow cytometry technology (multicolor flow cytometry + mass spectrometry).
It is planned to carry out the development and purification of RAS70 target peptide, as well as its conjugation with fluorescent labels in the infrared range.
Work will be done to perform in-depth in vitro molecular assessment of the effect of the bacterial strain GURSA on cultures of human tumor cells (epithelial, stromal and glial) using the ExCelligence technology.
It is planned to create a database of colposcopic images and conduct primary training of a neural network by binary classification (health/disease). The main ways of building an algorithm for evaluating ultrasound images and videos will be determined.
A personalized decision support system will be developed to choose tactics in patients with malignant tumors of various sites and severe cardiovascular comorbidities.
A panel will be developed for targeted next-generation sequencing and metabolomic profiling to identify prognostically unfavorable genetic alterations in patients with CNS and borderline pancreatobiliary tumors.
Treatment will be continued for patients with recurrent and refractory CNS tumors using metronomic chemotherapy in combination with mTOR inhibitors.
As part of adapting the single-cell sequencing technology, work will be done to obtain heterogeneous tumor lines containing genes of interest and barcode libraries for the subsequent implementation of single-cell sequencing technology.
A laboratory production procedure will be created, along with a complex of studies to determine quality indicators, and specifications for the main indicators will be developed: identification, volumetric activity, radiochemical purity, radionuclide impurities, chemical impurities, packaging, labeling, storage, study of their microbiological characteristics; a quality standard for each radiopharmaceutical will be created, prototypes will be developed.
The principles of personalized microbial therapy for colorectal cancer and other gastrointestinal tumors will be developed and the proper type of autoprobiotic strain will be selected based on the characteristics of the tumor and antibiotic therapy received by the patient.
Current palliative endoscopic procedures will be improved to improve reproducibility, efficacy, and quality of life for patients. New procedures will be developed for personalized palliative cancer treatment and modalities for their preclinical trials will be developed.
Personalized decision-making approaches will be developed to choose tactics in patients with malignant tumors of various sites and severe cardiovascular comorbidities.
A targeted therapy method will be developed based on the results obtained from the molecular genetic profiling of patients with CNS tumors and with determination of a possible effective combination of chemotherapy and targeted therapy.
Preclinical trials will be conducted for drugs for the treatment of colorectal cancer and multiple myeloma.
Preclinical trials will be conducted to analyze the diagnostic potential of the RAS70 peptide on patient-derived tumor xenografts in immunodeficient animals.
Preclinical trials will be conducted to investigate the effect of oncolytic bacteria on immunodeficient mice injected with antigen-positive genetically engineered and linear human tumor cells.
New data will be obtained on the possibilities of using autoprobiotics to treat the adverse effects of chemotherapy in patients with hematological malignancies. The ExCelligence technology will be used to assess and analyze the possible effect of chemotherapy drugs on the growth of autoprobiotics.
Preclinical trials of biomedical cell products (BMCPs) for colorectal cancer treatment will be carried out.
Preclinical trials will be conducted to assess the safety and toxicity of fluorescent antitumor conjugates, and clinical trials will be initiated to assess the efficacy of the drug in cancer patients.
Studies will be carried out on personalized autoprobiotic selection for patients with cancer and hematological malignancies. The association of the effects of therapy and treatment results with the patient's microbiocenosis and autoprobiotic therapy will be analyzed.
The final software product (Neural Network Algorithm) for the early diagnosis of cervical cancer in a clinical setting will be validated.
The safety of ovarian tissue cryopreservation will be assessed by assessing the overall survival and quality of life in girls after curative treatment of malignant tumors with preliminary cryopreservation of ovarian tissue.
New data will be obtained on somatic mutations leading to multiple parathyroid lesions.
Pilot batches of biomedical cell products for multiple myeloma treatment will be produced; laboratory and planned production procedures for the product will be prepared.
Targets for the creation of new drugs for the treatment of myeloproliferative disorders will be identified.
A personalized disease progression model will be created based on the obtained data of new generation sequencing and single-cell sequencing in hematological malignancies. The method of single-cell sequencing over the study period will be defined as a method for determining tumor heterogeneity and treatment strategies, as well as predicting survival.
A pilot clinical trial of RAS70 peptide agent for epifluorescence imaging of tumors will be initiated.
Based on the results of preclinical studies of oncolytic bacteria, a trial master file will be prepared and large-scale phase 1 volunteer trials will be conducted to assess the pharmacokinetics, pharmacodynamics and safety of the developed drug.
Algorithms for autoprobiotic therapy will be developed and guidelines for using personalized microbial therapy in the treatment of cancer and hematological malignancies will be elaborated.
As part of the project studying the role of microbiota in the development of female reproductive cancer, data on a panel of microorganisms will be generated, which can be used to diagnose the conditions of interest and assess the dynamics of treatment.